Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: A review

摘要: This paper reviews data on the prognosis of gastrointestinal stromal tumors (GISTs). These are specific KIT-expressing and KIT-signaling-driven mesenchymal tumors, many which have KIT-activating mutations. GISTs occur in entire (GI) tract may also arise from omentum, mesenteries, retroperitoneum. They range small benign to sarcomas at all sites occurrence. A KIT tyrosine kinase inhibitor, STI-571 (imatinib [Gleevec]; Novartis, Basel, Switzerland), has recently shown promise treatment metastatic GISTs. Understanding natural history GIST before introduction will help assess impact position this new treatment. The frequency versus malignant varies between sites. Benign outnumber stomach, whereas more common intestines. Tumors that metastasized presentation a very poor prognosis. Traditionally, 3 key prognostic factors been mitotic rate, tumor size, site. ( 5/50 HPFs usually behavior. Ki67 index identify with potential, but large site-specific series not yet available. Genetic markers, including DNA-copy number changes, telomerase activity, mutation status, be useful accurately identifying potential.